Gene therapy biotech bluebird bio files for a $86 million IPO

By
A A A

bluebird bio, a clinical-stage biotech focused on treating severe genetic and orphan diseases with gene therapy, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. The Cambridge, MA-based company, which was founded in 1992 and booked $1 million in collaboration revenue in the first quarter of 2013, plans to list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on March 21, 2013. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: BLUE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

86,627,350
  • $61.80 ▼ 3.33%
58,636,005
  • $15.44 ▼ 1.03%
43,254,709
  • $64.8725 ▼ 0.15%
39,355,269
  • $3.38 ▲ 0.90%
39,064,711
  • $4.29 ▲ 1.42%
38,037,134
  • $95.035 ▼ 0.37%
36,100,193
  • $94.66 ▼ 0.32%
32,857,379
  • $26.20 ▼ 0.46%
As of 7/10/2014, 04:04 PM